linjc16/ctgov huggingface dataset:
Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD.

Official Title
-----------------
Factors Determining Quality of Life Related to Respiratory Status According to Gender of COPD Patients Followed by a Pneumologist

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient who has a clinical visit for their usual follow-up. patient with COPD with at least a three month follow up Exclusion Criteria: Current or history of asthma Current participation in an interventional clinical study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of life, COPD patients, Evaluation According to Gender the Determining Independent Factors of Quality of Life Related to Respiratory Status of Patient With Moderate to Severe COPD
Influence of Intra-abdominal Ropivacaine 0.5% Spray on Postoperative Analgesia in Laparoscopic Surgery.

Study Overview
=================
Brief Summary
-----------------
Assessing postoperative pain after ropivacin 0.5% spray in the abdominal cavity during laparoscopic surgery.

Official Title
-----------------
Influence of Intra-abdominal Ropivacaine 0.5% Spray on Postoperative Analgesia in Laparoscopic Surgery.

Conditions
-----------------
Pain, Acute

Intervention / Treatment
-----------------
* Drug: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Appendectomy or cholecystectomy surgery Exclusion Criteria: Allergy to local anesthetics Intolerance to tramadol HCl Patient with peritonitis Pregnant women Surgery without laparoscopy Chronic pain before the operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ropivacaïne 0,5%<br>3 mg/kg of ropivacaine 0.5% sprayed into the abdominal cavity | Drug: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery<br>* Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation<br>|
| Placebo Comparator: NaCl 0,9%<br>NaCl 0,9% sprayed into the abdominal cavity | Drug: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery<br>* Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient's pain | The patient's satisfaction was assessed by visual analog scale, ranging from one (worse outcome )to four (better outcome | During appendectomy and cholecystectomy surgery |
Effectiveness of a Therapeutic Education Program in Improving Quality of Life of Children With ADHD and Their Parents

Study Overview
=================
Brief Summary
-----------------
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by attention deficit, impulsivity and hyperactivity. It's one of the most frequently encoutered disorder in child psychiatry. ADHD has a significant impact on the quality of life of children and their parents. In the child psychiatry department of the MPEA Peyre Plantade, a Therapeutic Education program specific to ADHD has been set up for children and their parents. This program consists of different workshops whose aim is to reduce the ADHD repercussions on the daily life of children and their families and thus improve their quality of life. The principal aim of our study is to evaluate the effectiveness of this program in improving the quality of life of children with ADHD and their parents.

Official Title
-----------------
Evaluation of the Effectiveness of the Therapeutic Education Program Living Better With ADHD in Improving the Quality of Life of Children With ADHD and Their Parents

Conditions
-----------------
Attention Deficit Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Aged 8 to 13 With a diagnosis of ADHD Living in the herault department Participatinf in the therapeutic education program  Living Well with ADHD  Exclusion criteria: Parent's objection to the use of data collected Parent unable to complete questionnaires

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life of children | To Evaluate the effectiveness of the therapeutic education program Living better with ADHD in improving quality of life of children with ADHD measured by the Kidscreen 27 questionnaire (Total score & sub score) | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Therapeutic Education, Quality of life
Risk of Bacterial Exposure to the Anesthesiologist's Face During Intubation and Extubation

Study Overview
=================
Brief Summary
-----------------
The practice of intubation and extubation is not without risks to the anesthesiologists. Especially, the face of health care worker is the body part most commonly contaminated by splashes and sprays of body fluids. The aim of this study is to determine the incidence of unrecognized exposure to the anesthesiologists' face during endotracheal intubation and extubation. We will perform face shield swab before and after the endotracheal intubation and extubation. All swabs will be cultured for 48 hours and the number of colony forming units before and after the procedures (intubation/extubation) will be compared.

Official Title
-----------------
Risk of Bacterial Exposure to the Anesthesiologist's Face During Intubation and Extubation

Conditions
-----------------
Anesthesiologists Who Perform Endotracheal Intubation and Extubation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: anesthesiologists who perform endotracheal intubation and extubation for patients scheduled for endotracheal intubation for elective surgeries Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| anesthesiologists who will perform endotracheal intubation and extubation for general anesthesia<br>All anesthesiologists in this study will use face shield for facial protection. Face shield swab will be done before and after the procedures (intubation and extubation) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bacterial growth of face shield swab after the endotracheal extubation | All swab will be cultured for 48 hours and will be reported as no growth or by number of colony forming unit(CFU)s. The number of CFU of post-extubation swab will be compared with that of pre-extubation swab. | Bacterial swab will be performed 5 minutes after the endotracheal extubation (after the confirmation of sufficient spontaneous breathing) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bacterial growth of face shield swab after the endotracheal intubation | All swab will be cultured for 48 hours and will be reported as no growth or by number of colony forming unit(CFU)s. The number of CFU of post-intubation swab will be compared with that of pre-intubation swab. | Bacterial swab will be performed 5 minutes after the endotracheal extubation (after the confirmation of adequate mechanical ventilation) |
Acceptability of HPV Self-sampling Among Canadian Women Aged 21 to 65

Study Overview
=================
Brief Summary
-----------------
We propose a cross-sectional study to explore the acceptability and feasibility of HPV self-sampling among Quebec women. The study will invite eligible women to self-sample for HPV at home. The HPV risk factors of patients included in the study will be taken into consideration (vaccination, smoking, number of partners, date of last screening, etc.).

Official Title
-----------------
Prévention du Cancer du Col de l'UTÉrus Par dépistage d'Une Infection Partageable Sexuellement

Conditions
-----------------
HPV Infection, Cervical Cancer Screening

Intervention / Treatment
-----------------
* Diagnostic Test: HPV self-sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Speak and understand French without help Have internet access (for completing forms) Have a mailing address Exclusion Criteria: Known positive HPV status • Have already had a hysterectomy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HPV self-sampling group<br> | Diagnostic Test: HPV self-sampling<br>* HPV self-sampling (Cobas Uniswab)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the acceptability of HPV self-sampling by patients | percentage of patients who prefer HPV testing to traditional cytology | 2 months following recruitment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the percentage of samples collected correctly by patients |  | 2 months following recruitment | 
| Evaluate the return rate of mailed kits |  | 2 months following recruitment | 
| Calculate the HPV positivity rate in a population sample |  | 2 months following recruitment |
Predicting Abdominal Reoperation

Study Overview
=================
Brief Summary
-----------------
Nationwide retrospective study, to predict the risk of abdominal reoperation.

Official Title
-----------------
Predicting Long-term Risk of Reoperations Following Abdominal and Pelvic Surgery: a Nationwide Retrospective Cohort Study

Conditions
-----------------
Surgery, Abdominal Adhesion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing first abdominal or pelvic surgery between June 1st 2009 and June 30th 2011 in Scotland. Exclusion Criteria: Positive history for abdominal surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with first abdominal surgery in Scotland between 2009 and 2011<br>Patients with first abdominal surgery in Scotland between 2009 and 2011 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with an abdominal reoperation in the study cohort | Number of patients undergoing a reoperation after abdominal surgery | within 5 years postoperatively |
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy

Study Overview
=================
Brief Summary
-----------------
Homocysteine, a well-known inducer of vascular endothelial cell damage has been associated with extracellular matrix changes. Many studies demonstrated that high levels of this aminoacid in diabetic patients increases significantly the risk of the development of this pathology. This study has been undertaken to investigate the role of homocysteine and its cofactors (folic acid, vitamin B6 and B12) during the progression of the diabetic retinopathy.

Conditions
-----------------
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Folic Acid, vit B6 and B12
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetic patients with proliferative and non proliferative retinopathy Exclusion Criteria: Patients with chronic liver disease Patients with kidney disease.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Folic Acid, vit B6 and B12<br> | Drug: Folic Acid, vit B6 and B12<br> <br> |
| Placebo Comparator: Sugar pill<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| homocysteine |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| folic acid |  | 12 months |
The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia

Study Overview
=================
Brief Summary
-----------------
To determine if platelet dysfunction and/or pharmacologic drug interaction occurs in patients taking both AZT and ibuprofen, which might account for enhanced bleeding tendency.

Official Title
-----------------
Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs

Conditions
-----------------
HIV Infections, Hemophilia A

Intervention / Treatment
-----------------
* Drug: Ibuprofen
* Drug: Zidovudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Hemophilia. HIV-seropositivity confirmed by Western Blot. Prior Medication: Required: - AZT for study patients. Allowed: - Ibuprofen. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Hospitalization for opportunistic infection, bacterial infection or malignancy. Concurrent Medication: Excluded: AZT (for control group). Antibiotics or other medication for opportunistic infection, bacterial infection, or malignancy. Patients with the following prior conditions are excluded: Hospitalization for opportunistic infection, bacterial infection, or malignancy. Required: Ibuprofen. AZT 1-2 gm daily (for study patient) or not taking AZT (for control).

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ibuprofen|nan|
|Drug: Zidovudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood Platelets, Ibuprofen, Drug Interactions, Zidovudine, Hemophilia A
A Prospective Cohort Study of Aged People for Chronic Diseases

Study Overview
=================
Brief Summary
-----------------
This study is a hospital-based, prospective cohort study to elucidate the predictive factors including muscle and fat mass for chronic diseases and mortality in elderly persons aged 60 years and older.

Detailed Description
-----------------
This study is a hospital-based, prospective cohort study to elucidate the predictive factors among anthropometric and biochemical parameters and body composition information for chronic diseases including diabetes mellitus, myocardial infarction, stroke, osteoporosis, fracture, and cognitive dysfunction, and mortality in elderly persons aged 60 years and older.

Official Title
-----------------
A Hospital-based Prospective Cohort Study With Aged People to Elucidate Predictive Factors Including Muscle and Fat Mass for Chronic Diseases and Mortality

Conditions
-----------------
Aging, Sarcopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 60 years and older Capable of communication with the research team Provided written informed consent Exclusion Criteria: Age < 60 years active malignancy uncompensated liver cirrhosis ESRD severe cognitive impairment which cannot communicate with the research term

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HAPPY Cohort<br>A elderly cohort for chronic diseases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alll cause mortality |  | 9 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiometabolic mortality |  | 9 years | 
| Incidence of major adverse cardiac event including nonfatal myocardial infarction, nonfatal stroke, and unstable angina |  | 9 years | 
| Incidence of frailty defined by the Korean Fraility Index |  | 9 years | 
| Incidence of osteoporotic fracture |  | 9 years | 
| Incidence of cognitive dysfunction measured by minimental status examination |  | 9 years | 
| Development of sarcopenia defined by the Foundation for the National Institutes of Health (FNIH) criteria |  | 9 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sarcopenia, sarcopenic obesity, osteoporosis, fracture, cardiovascular disease, mortality
Prochlorperazine vs Metoclopramide

Study Overview
=================
Brief Summary
-----------------
Migraine headaches are a common reason for patients to present to an emergency department. We are comparing two different medications to see which one is better for patients who present ot an emergency room with a migraine headache.

Detailed Description
-----------------
One-third of the five million headache patients who present to US Emergency Departments (ED) annually have a migraine headache. The anti-emetic dopamine receptor antagonists have proven efficacy for migraines, are at least as well-tolerated as triptans, and enjoy wide-spread use in North American EDs. However, it is not yet clear which medication within this class and which dosage is optimal. Therefore, we propose a randomized clinical trial to compare the efficacy and tolerability of two standard medications for migraine. Specific Aim: To compare the efficacy of metoclopramide versus prochlorperazine for the emergency department treatment of migraine headaches. Both of these medications will be combined with diphenhydramine to prevent extra-pyramidal side effects. Patients will be enrolled as participants if they present to one of the participating EDs and consent to participate. Medications will be administered as an intravenous drip over 15 minutes. Rescue medication will be administered, if needed, after one hour. A follow-up phone call will be conducted 24 hours after the ED visit.

Official Title
-----------------
Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: Prochlorperazine
* Drug: Metoclopramide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Present to the Ed with an acute migraine headache Exclusion Criteria: secondary headache if the patient is to receive a lumbar puncture in the ED maximum temperature greater than 100.3 degrees new objective neurologic abnormality at the time of physical exam allergy or intolerance to a study medication pregnancy previous enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Prochlorperazine|nan|
|Drug: Metoclopramide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| One hour pain scores |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| One hour, two hour and 24 hour pain, functional disability scores, and side effect profiles. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Migraine, Headache